Key result
Dexrazoxane reduces heart failure risk in advanced breast cancer receiving high-dose anthracyclines, though evidence gaps remain.
Why the study?
Despite FDA approval and evidence that dexrazoxane reduces heart failure risk in adults treated with high-dose anthracyclines, its use remains infrequent due to evidence gaps in cardiac safety and cancer outcomes in modern treatment regimens and diverse adult populations.
Identifies critical evidence gaps that currently limit the use of dexrazoxane for cardioprotection in modern anthracycline regimens, proposing future research directions.
Evidence gaps limit dexrazoxane adoption in modern regimens; prospective trials needed to define its role in cardio-oncology.
Heart, Lung, and Blood Institute priorities, which promote collaborative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes.
No takes yet. Share an insight, caveat, or question.
Upshaw et al. (2024) conducted a review in Anthracycline-induced cardiotoxicity. Dexrazoxane was evaluated. Dexrazoxane reduces the risk of heart failure in adults with advanced breast cancer treated with high-dose anthracyclines, but evidence gaps limit its modern use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: